Technical Analysis for LPCN - Lipocine Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 1.59 | 4.61% | 0.07 |
Earnings due: Mar 11
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical LPCN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Spinning Top | Other | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 4.61% | |
| Below Lower BB | Weakness | 4.61% | |
| Lower Bollinger Band Touch | Weakness | 4.61% | |
| Oversold Stochastic | Weakness | 4.61% | |
| 50 DMA Resistance | Bearish | -3.05% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Down 3% | 1 day ago | |
| Down 2 % | 1 day ago | |
| Rose Above Lower Bollinger Band | 1 day ago | |
| Down 1% | 1 day ago | |
| Up 5% | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 03/11/2021
Lipocine Inc. Description
Lipocine Inc., a specialty pharmaceutical company, is engaged in the development of pharmaceutical products in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates that are used to produce pharmacokinetic characteristics; facilitate lower dosing requirements and bypass first-pass metabolism; reduce side effects; and eliminate gastrointestinal interactions that limit bioavailability. Its product candidates for men's health include LPCN 1021, an oral product candidate, which is in Phase III clinical trials; and LPCN 1111, an oral product candidate that is in Phase I/II clinical trials for the treatment of testosterone replacement therapy. The company's product candidates for women's health comprise LPCN 1107, which is in Phase I/II clinical trials for the prevention of preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pharmaceutical Products Gastrointestinal Clinical Research Clinical Trial Alcohols Metabolism Bypass Ketones Testosterone Androstanes Testosterone Replacement Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.42 |
| 52 Week Low | 0.3 |
| Average Volume | 4,601,595 |
| 200-Day Moving Average | 1.45 |
| 50-Day Moving Average | 1.69 |
| 20-Day Moving Average | 1.82 |
| 10-Day Moving Average | 1.76 |
| Average True Range | 0.17 |
| ADX | 22.76 |
| +DI | 17.21 |
| -DI | 30.09 |
| Chandelier Exit (Long, 3 ATRs ) | 1.78 |
| Chandelier Exit (Short, 3 ATRs ) | 1.97 |
| Upper Bollinger Band | 2.13 |
| Lower Bollinger Band | 1.50 |
| Percent B (%b) | 0.14 |
| BandWidth | 34.35 |
| MACD Line | -0.04 |
| MACD Signal Line | 0.02 |
| MACD Histogram | -0.0554 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.85 | ||||
| Resistance 3 (R3) | 1.84 | 1.74 | 1.81 | ||
| Resistance 2 (R2) | 1.74 | 1.68 | 1.75 | 1.79 | |
| Resistance 1 (R1) | 1.67 | 1.64 | 1.71 | 1.68 | 1.78 |
| Pivot Point | 1.57 | 1.57 | 1.59 | 1.57 | 1.57 |
| Support 1 (S1) | 1.49 | 1.50 | 1.53 | 1.50 | 1.40 |
| Support 2 (S2) | 1.39 | 1.46 | 1.40 | 1.39 | |
| Support 3 (S3) | 1.32 | 1.39 | 1.37 | ||
| Support 4 (S4) | 1.33 |
